FindTrial
Sign In

“ULTRASOUND-GUIDED LOCAL OZONE INJECTION VS CORTICOSTEROID INJECTION IN PLANTAR FASCIITIS"

“ULTRASOUND-GUIDED LOCAL OZONE VERSUS CORTICOSTEROID INJECTION IN PATIENT WITH PLANTAR FASCIITIS AT A TERTIARY CARE HOSPITAL IN INDIA - A RANDOMIZED DOUBLE BLINDED CONTROLLED TRIAL ? - NA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058290
Enrollment
50
Registered
2023-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M708- Other soft tissue disorders related to use, overuse and pressure

Interventions

Intervention1: ULTRASOUND GUIDED LOCAL OZONE INJECTION AND LOCAL METHYLPREDNISOLONE INJECTION: At first, the details of the procedure will be explained to the patients. After taking informed consent f

Sponsors

AIIMS BHUBANESWAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Plantar fasciitis with pain not relieving after three months or more with conventional physical exercises and footwear modification 2. Tenderness while palpating of the medial calcaneal tubercle or plantar fascia on its insertion 3. Pain intensity = 4 or more in Visual analog scale (VAS) score 4. Plantar fascia thickness of more than 4 mm with hypoechoic change at the insertion point of the calcaneum on ultrasound

Exclusion criteria

Exclusion criteria: 1. Any trauma to the ankle or calcaneal 2. Tibial nerve neuropathy (Positive Tinel’s sign) 3. Any history of systemic inflammatory or connective tissue disease, vascular insufficiency or peripheral neuropathy causing heel pain 4. Lumbar disc herniation with radiating pain to the lower limb 5. Systemic diseases like uncontrolled diabetes or gout 6. Any heel surgery done or local injections taken within the last six months 7. Any local lesion in the injection site 8. Coagulation disorder, Allergic reaction to local anesthetic, ozone, and steroid in past, pregnancy 9. Switch to any other treatment modality during the 12 weeks of follow up in post injection period. 10. Refusal to consent

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale (VAS) of painTimepoint: AT BASELINE AND 2,6,12 WEEKS AFTER INJECTION—

Secondary

MeasureTime frame
1. Foot function assessment using FAAM scale 2. Plantar fascia thickness measurement using ultrasound Timepoint: AT BASELINE AND 2,6,12 WEEKS AFTER INJECTION—

Countries

India

Contacts

Public ContactDR PARAG GOSWAMI

ALL INDIA INSTITUE OF MEDICAL SCIENCE,BHUBANESWAR

pmr_jagannath@aiimsbhubaneswar.edu.in8876842376

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026